In addition, increased levels of RNASEH2A in cancer compared to normal tissues and cells were also reported in cervical cancer [19], prostate cancer [20], colorectal carcinoma [21], and triple negative breast cancer [22]. This evidence concerns the gene RNASEH2A and cancer.